SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject5/1/2002 12:43:14 PM
From: teevee  Read Replies (1) of 631
 
Isotechnika Inc. (ISA-T) C$4.97
Preliminary Phase II-A Kidney Transplant Results Promising - Strong BUY
David Wingnean,
Eric Lun (Associate),
Stuart Wollach (Associate),
(TD Securities-Biotech/Health Care)

Isotechnika's Dr. Launa Aspeslet, VP QA and Regulatory Affairs, presented preliminary
results of its phase II-A kidney transplant study at the prestigious American Transplant
Congress in Washington, DC. In front of over a thousand transplant surgeons and
nephrologists, Dr. Aspeslet revealed that in the first six patients who finished a 12-week
course of ISAtx247, all patients exhibited stable serum creatinine (SCr) levels, indicating
that ISAtx247 is not kidney toxic. Dr. Aspeslet also revealed data that ISAtx247, using a
CN-inhibitor blood test, is 3X more potent than Neoral™ (cyclosporine). To reflect the
increased potency, ISA has modified the study protocol to dose ISAtx247 at 1/3 trough
levels of Neoral™ (previously 1/2). Dr. Aspeslet also mentioned some early results of the
phase II psoriasis study where there was also no evidence of kidney toxicity in the over 150
patients enrolled to date (4/5 subjects received ISAtx247). These are early, but very
promising results.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News